Panel requires stricter safety criteria for blood system trial

11/17/2009 | Forbes

The FDA's Blood Products Advisory Committee has required Cerus to tighten safety parameters for a late-stage study involving its intercept blood system, which inhibits blood-borne pathogens in blood components used for transfusions. The company said it may take a year to finish preparations for the planned trial.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ
RN Care Manager
MJHS
Brooklyn, NY
Director of Utilization Management
Meridian Health Plan
Chicago, IL
Senior Manager, Healthcare Reform
Avalere Health
Washington, DC